Summary of the five lowest-cost portfolio options that achieve the global coverage rate of 84.2% possible under the assumption of “minimum acceptable” characteristics for the new vaccine technologies.

All values indicate the average per year over a 10-year period that incorporates population growth. Annual Portfolio Cost, given as NPV, is the buyer-side cost and includes purchase price, service delivery cost, and amortized R&D or capital investments.